Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PATH

Chairs: Selim M. Arcasoy, MD, MPH and Mark Greer, MB Bch
 

10:30 AM	(12) Diffusing Capacity for Carbon Monoxide (DLCO): A Predictor of CLAD and Death after Lung Transplantation in a 20-Year Longitudinal Study D. R. Darley1, J. Ma2, E. Huszti2, R. Ghany1, M. Hutcheon1, C. Chow1, J. Tikkanen1, S. Keshavjee1, L. G. Singer1, T. Martinu1. 1Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, 2Biostatistics Research Unit, University Health Network, Toronto, ON, Canada
10:45 AM	(13) Molecular Analysis of Transbronchial and Mucosal Biopsies in Patients with CLAD M. Parkes1, P. F. Halloran1, J. Chang1, K. S. Famulski1, J. Reeve1, R. Hachem2, P. Jaksch3, S. Juvet4, W. Klepetko3, S. Keshavjee4, D. Kreisel2, A. Roux5, G. I. Snell6, E. Trulock2, I. L. Timofte7, G. P. Westall6, K. M. Halloran1. 1University of Alberta, Edmonton, AB, Canada, 2Washington University School of Medicine, St. Louis, MO, 3Medical University of Vienna, Vienna, Austria, 4University Health Network, Toronto, ON, Canada, 5Hôpital Foch, Surenes, France, 6Monash University, Melbourne, Australia, 7University of Maryland, Baltimore, MD
11:00 AM	(14) Predictive Biomarkers for Bronchiolitis Obliterans V. Kaza1, C. Zhu1, L. Feng1, A. Reddy2, C. Lacelle3, L. Terada1, M. Manish1, S. Bollineni1, A. Banga1, F. Torres1, J. Mullins1, Q. Li4. 1UT SW Med Ctr, Dallas, TX, 2Southwest Pulmonary Associates, Dallas, TX, 3UT Southwestern Medical Center, Dallas, TX, 4Ut SW Med Ctr, Dallas, TX
11:15 AM	(15) Chest CT Has Prognostic Value at BOS Diagnosis after Lung Transplantation A. Van Herck1, A. Sacreas1, T. Heigl1, J. Kaes1, A. Vanstapel1, S. E. Verleden1, B. M. Vanaudenaerde1, W. De Wever2, G. M. Verleden1, R. Vos1. 1Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing, University of Leuven, Leuven, Belgium, 2Department of Radiology, University Hospitals Leuven, Leuven, Belgium
11:30 AM	(16) Regulatory T Cells in Asymptomatic ISHLT Grade A1 Rejection and the Risk of Chronic Lung Allograft Dysfunction M. White, L. Levy, S. Moshkelgosha, G. Zehong, S. Keshavjee, T. Martinu, S. Juvet. Toronto Lung Transplant Program, Toronto General Research Institute, Toronto, ON, Canada
11:45 AM	(17) Emergence of a Specific Intrapulmonary CD4+ T Cell Subset Prior to the Onset of Lung Allograft Dysfunction S. Moshkelgosha1, L. Levy1, T. Martinu1, R. Zamel1, C. Guidos2, S. Keshavjee1, J. Yeung1, S. C. Juvet1. 1Toronto Lung Transplant Program, Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 2The Hospital for Sick Children (SickKids), Toronto, ON, Canada
12:00 PM	(18) Increased Hazard of Chronic Lung Allograft Dysfunction in the Presence of Persistent and Complement Fixing Donor-Specific Antibodies C. J. Iasella1, C. R. Ensor2, M. Marrari3, M. Mangiola3, C. A. Moore4, M. R. Morrell5, J. M. Pilewski5, J. D'Cunha6, P. Sanchez6, J. F. McDyer5, A. Zeevi3. 1Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, 2Department of Pharmacy, Florida Hospital, Orlando, FL, 3Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 4Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 6Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PATH

Chairs: Edward R. Garrity, Jr., MD and Cynthia J. Gries, MD, MSc
 

2:00 PM	(45) Increased Frequency Of regulatory CD127low T Cells and of IL2+ T Cells Early after Lung Transplant is Associated with Improved Graft Survival F. Ius1, J. Salman1, A. Knöfel1, T. Nakagiri1, W. Sommer1, T. Siemeni1, C. Kh ün1, T. Welte2, C. S. Falk3, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 3Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
2:15 PM	(46) Prognostic Significance of Mesenchymal Cell Colony Forming Units in Bronchoalveolar Lavage Fluid for Restrictive Chronic Lung Allograft Dysfunction M. P. Combs1, M. Xia2, D. S. Wheeler1, E. A. Belloli1, D. M. Lyu1, N. M. Walker1, S. Murray2, V. N. Lama1. 1Department of Medicine, University of Michigan, Ann Arbor, MI, 2Department of Biostatistics, University of Michigan, Ann Arbor, MI
2:30 PM	(47) Intragraft IgG Levels and Donor-Specific anti-HLA Antibodies in Different Phenotypes of Chronic Lung Allograft Dysfunction A. Sacreas1, J. Taupin2, A. Van Herck1, J. Kaes1, T. Heigl1, A. Vanstapel1, M. Emonds3, L. Daniëls3, R. Vos1, G. M. Verleden1, B. M. Vanaudenaerde1, A. Roux4, S. E. Verleden1. 1Leuven Lung Transplant Unit, Department of Chronic Diseases, Metabolism, and Ageing (CHROMETA), KU Leuven, Leuven, Belgium, 2Laboratoire d'Immunologie et Histocompatibilité, Saint-Louis Hospital, Paris, France, 3Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium, 4Service de Transplantation Pulmonaire, Foch Hospital, Suresnes, France
2:45 PM	(48) Airway Transcriptome Analysis and Immune Proteome Profiling of the Lung Allograft Reveals Novel Immune Signatures in Chronic Lung Allograft Dysfunction C. J. Iasella1, A. Hoji2, Y. Zhang2, W. Xu2, K. Chen2, M. Brown2, E. Lendermon2, B. A. Johnson2, S. Kilaru2, M. R. Morrell2, J. M. Pilewski2, J. F. McDyer2. 1Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh, Pittsburgh, PA
3:00 PM	(49) Host miRNA Profile of Aspergillus Colonization Resulting in CLAD in Lung Transplant Recipients W. Gohir1, W. Klement2, L. G. Singer3, S. M. Palmer4, S. Keshavjee3, S. Husain1. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Organ Donation and Transplantation, Canadian Blood Services, Ottawa, ON, Canada, 3Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 4Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC
3:15 PM	(50) Identification and Characterization of Patients With a Mixed Phenotype of CLAD S. E. Verleden1, J. Von der Thusen2, A. Van Herck1, B. Weynand1, E. Verbeken1, J. Verschakelen1, A. Dubbeldam1, B. Vanaudenaerde1, D. Van Raemdonck1, R. Vos1, G. Verleden1. 1KU Leuven, Leuven, Belgium, 2Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
3:30 PM	(51) Exploring Chronic Lung Transplant (LTx) Allograft Dysfunction (CLAD): The Potential Clinical Prognostic Relevance of Single Bite Transbronchial Biopsy (TBB) Microarray G. I. Snell1, G. Westall1, Y. Cristiano1, B. J. Levvey1, L. Sullivan1, K. Halloran2, P. Halloran3. 1Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 2Lung Transplant and Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Medicine, University of Alberta, Edmonton, AB, Canada

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PATH

Session Summary: The recognition that not all cases of lung allograft dysfunction could be described accurately within the bronchiolitis obliterans syndrome (BOS) terminology led to the development of a new overarching descriptor (CLAD) to embrace both obstructive and restrictive allograft dysfunction. How to detect, diagnose, and manage suspected cases is described based on sound physiological and radiological principles. Exclusion criteria are discussed as well as special circumstances.

Chairs: Christian Benden, MD and Sofya Tokman, MD
 

4:15 PM	CLAD: Definition and Beyond Geert Verleden, MD, Univ Hospital Gasthuisberg, Belgium, Belgium
4:30 PM	CLAD Phenotypes: Why Split? Jamie Todd, MD, Duke University, Durham, NC, USA
4:45 PM	Restrictive Allograft Syndrome: Definition and Diagnosis Masaaki Sato, MD, University of Tokyo, Tokyo, Japan
5:00 PM	Restrictive Allograft Syndrome: Pathology Jan H. von der Thüsen, MD PhD, Erasmus Medical Center, Rotterdam, Netherlands
5:15 PM	Risk Factors and Prognosis of Restrictive Allograft Syndrome Gregory I. Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia
5:30 PM	CLAD Treatment: The Kingdom of the Near Dead? Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, ON, Canada
5:45 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PATH, PHARM

Chairs: Joshua Mooney, MD and Tanya J. McWilliams, MD, PhD
 

6:15 PM	(1030) Early Shift of Lung Perfusion to the Unilateral Lung Predicts the Development of Unilateral Chronic Lung Allograft Dysfunction after Bilateral Living-Donor Lobar Lung Transplantation H. Yamamoto, S. Sugimoto, T. Kurosaki, S. Otani, M. Okazaki, M. Yamane, S. Toyooka, T. Oto. General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan
6:20 PM	(382) Bronchoalveolar Lavage Pentraxin 3 Levels during Clinically-Stable Minimal Acute Rejection are Associated with CLAD and Death Risk L. Levy1, E. Huszti2, R. Ghany1, M. Ahmed1, S. Hunter1, K. Zhang1, K. Boonstra1, W. Klement1, S. Moshkelgosha1, J. Tikkanen1, L. Singer1, S. Keshavjee1, S. Juvet1, T. Martinu1. 1Toronto Lung Transplant Program, Toronto, ON, Canada, 2Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada
6:25 PM	(383) Impact of mir21 Expression in Chronic Lung Allograft Dysfunction after Lung Transplantation N. Miyahara1, A. Benazzo1, F. Oberndorfer2, P. Jaksch1, W. Klepetko1, K. Hoetzenecker1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Pathology, Medical University of Vienna, Vienna, Austria
6:30 PM	(384) Quantiferon®-Monitor: A Potential Biomarker of Immunosuppression in Lung Transplantation B. J. Gardiner1, Y. Cristiano2, B. J. Levvey2, G. I. Snell2, A. Y. Peleg1, G. P. Westall2. 1Infectious Diseases, Alfred Hospital & Monash University, Melbourne, Australia, 2Respiratory Medicine & Lung Transplantation, Alfred Hospital & Monash University, Melbourne, Australia
6:35 PM	(385) Lung Bacterial Burden is Increased Following the Onset of Chronic Rejection M. P. Combs, D. S. Wheeler, J. Luth, N. M. Walker, R. P. Dickson, V. N. Lama. Department of Medicine, University of Michigan, Ann Arbor, MI
6:40 PM	(386) The Impact of Pharmacogenomics on Tacrolimus Dosing and Levels among Lung Transplant Recipients A. W. Brown1, J. Peterson1, M. Fregoso1, M. Nayyar1, A. Cochrane1, J. Pluhacek1, M. Lemma1, S. Aryal1, O. A. Shlobin1, C. S. King1, R. Iyer2, J. F. Deeken2, S. D. Nathan1. 1Inova Advanced Lung Disease & Transplant, Fairfax, VA, 2Inova Translational Medicine Institute, Fairfax, VA
6:45 PM	(387) Extracorporeal Photopheresis (ECP) in the Management of Chronic Lung Allograft Dysfunction Y. Furuya1, C. Witt1, E. P. Trulock1, D. Byers1, H. Kulkarni1, L. K. Tague1, P. Aguilar1, D. Kreisel2, V. Puri2, A. Gelman2, R. Hachem1. 1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, MO, 2Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO
6:50 PM	(388) Five-Year Results of an IgA and IgM-Enriched Human Immunoglobulin G-Based Therapy for Early Anti-HLA Donor Specific Antibodies in 158 Lung-Transplanted Patients F. Ius1, M. Verboom2, W. Sommer1, C. Müller3, M. Hallensleben2, J. Salman1, T. Siemeni1, C. Kühn1, M. Avsar1, D. Bobylev1, N. Schwerk3, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Department of Paediatrics, Hannover Medical School, Hannover, Germany
6:55 PM	(389) Donor-Specific Antibodies and Antibody-Mediated Rejection after Alemtuzumab Induction Therapy: A Retrospective Analysis of a High-Volume Lung Transplant Center A. Benazzo1, S. Schwarz1, S. Geleff2, D. Weber3, G. Murakozy1, C. Lambers3, B. Moser1, J. Matilla1, G. Lang3, S. Taghavi1, W. Klepetko1, K. Hoetzenecker1, P. Jaksch1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, 3Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
7:00 PM	(390) Extravascular Lung Water Quantification in Donor Lungs K. S. Ayyat1, T. Okamoto1, H. Niikawa1, Y. Itoda1, S. Dugar1, S. Q. Latifi1, D. J. Lebovitz2, A. Moghekar1, K. R. McCurry1. 1Cleveland Clinic, Cleveland, OH, 2Lifebanc, Cleveland, OH
7:05 PM	(391) Precision Proteomics as Protein Biomarker Discovery in Detecting Chronic Lung Allograft Dysfunction H. Ghaider, M. Fakhro, S. Lindstedt. Cardiothoracic Surgery, Lund University Hospital, Lund, LUND, Sweden
7:10 PM	(392) Mid-Term Results of Lung Transplantation (LTx) after Bridging with Extracorporeal Membrane Oxygenation - Influence of Concomitant Invasive Mechanical Ventilation (iMV M. Monteagudo Vela1, D. Garcia Saez1, P. Mohite1, A. Reed2, F. De Robertis1, U. Stock1, B. Mahesh1, M. Carby2, A. Simon1, B. Zych1. 1Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom, 2Respiratory Medicine, Harefield Hospital, London, United Kingdom

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PHARM

Session Summary: As the number of older transplant patients continues to grow it becomes more important to understand age-associated immune changes, which may influence the impact of immunosuppression. Older lung transplant patients experience increased rates of infection, malignancy, and death, but decreased rates of rejection, suggesting over immune suppression. Yet at the same time, older transplant recipients experience increased levels of inflammation.

Chairs: Jonathan P. Singer, MD, MS and Hanneke Kwakkel-van Erp, MD, PhD
 

7:00 AM	Frailty and Pro-Inflammatory Cytokines: Potential Biomarkers for Poor Outcomes? Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA
7:15 AM	Q&A
7:20 AM	Immune Senescence and Transplantation: Balance Between Infection and Rejection Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA
7:35 AM	Q&A
7:40 AM	Challenges in Medication Administration in Older Transplant Patients Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland
7:55 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX

Chairs: Alexis Slama, MD and Daniel F. Dilling, MD
 

8:00 AM	(107) Validation of an EVLP Perfusate Diagnostic Test for the Prediction of Lung Transplant Outcomes A. T. Sage1, M. Richard-Greenblatt2, K. J. Zhong2, M. B. Snow1, M. Babits1, M. Chen1, H. Gokhale1, M. Galasso1, H. Shan1, M. Cypel1, M. Liu1, K. C. Kain2, S. Keshavjee1. 1Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada
8:15 AM	(108) A Clinical Trial Evaluating the Effects of Ultra-Violet C treatment (UVC) during Ex Vivo Lung Perfusion (EVLP) as a Method of Inactivating Hepatitis C Infection in Donor Lungs M. Cypel1, M. Galasso1, R. Ribeiro1, B. Wilson1, V. Bagnato2, C. Kurachi2, M. Chen1, D. Kumar1, T. K. Waddell1, L. G. Singer1, S. Keshavjee1, A. Humar1, J. Feld1. 1Toronto General Hospital, Toronto, ON, Canada, 2Sao Paulo University, Sao Carlos, Brazil
8:30 AM	(109) Stratification Risk Analysis in Bridging Patients to Lung Transplant on ECMO: The STABLE Recipient Risk Score A. Habertheuer, T. Richards, F. Sertic, M. Crespo, M. Molina, P. Vallabhajosyula, E. Cantu, Y. Suzuki, D. Diagne, C. Bermudez. Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
8:45 AM	(110) Ex-Vivo Lung Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus T. J. Ku1, M. Cypel2, R. V. Ribeiro2, V. H. Ferreira1, D. Kumar1, A. Humar1. 1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada
9:00 AM	(111) Early Outcomes with the Use of ExtraCorporeal Membrane Oxygenation as a Bridge to Combined Heart and Lung Transplant F. Sertic, M. M. Crespo, A. Habertheuer, D. Diagne, L. Chavez, T. Richards, M. Molina, Y. Suzuki, E. Rame, J. Wald, E. Cantu, C. Bermudez. University of Pennsylvania, Philadelphia, PA
9:15 AM	(112) Increasing Use of EVLP in the United States: Data from the OPTN/UNOS R. R. Lehman1, K. Uccellini1, E. Lease2, R. Daly3, K. M. Chan4. 1United Network for Organ Sharing, Richmond, VA, 2University of Washington, Seattle, WA, 3Mayo Clinic, Rochester, MN, 4University of Michigan, Ann Arbor, MI
9:30 AM	(113) Central Ambulatory Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation P. Downey1, W. Ragalie1, D. Ross2, A. Ardehali1. 1Cardiothoracic Surgery, UCLA, Los Angeles, CA, 2Pulmonary and Critical Care Medicine, UCLA, Los Angeles, CA

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: MCS

Session Summary: This symposium will bring experts in Ex-Vivo Lung Perfusion and donor lung management from all over the world. Current practices, different models, ongoing clinical trials with EVLP and added therapeutics will be discussed. The attendee will increase his or her understanding of the technique, its applications and future directions.

Chairs: John Dark, MB, FRCS and Tiago Machuca, MD, PhD
 

10:15 AM	Implementation of High Volume Clinical EVLP: The Toronto Model Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada
10:30 AM	Rationale for Portable EVLP Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany
10:45 AM	Benefits and Barriers of a Do-It-Yourself EVLP Program Peter Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia
11:00 AM	Organ Procurement Organization-based EVLP Program Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA
11:15 AM	Experience with a Third-Party EVLP Program Kenneth R. McCurry, MD, FACS, Cleveland Clinic, Cleveland, OH, USA
11:30 AM	The Role of Biomarkers in EVLP Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, UK
11:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Junior Faculty Clinical Case Reports: Lung Failure/Transplantation (Banda Sea 2)
(LF/LTX)   Poster Numbers: 1418-1442
 

---

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Lung Transplantation (Adult) (Hibiscus 1)
(LTX)   Poster Numbers: 795-824
 

---

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Lung Transplantation (Adult) (Hibiscus 1)
(LTX)   Poster Numbers: 825-853, 1029

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX

Chairs: David R. Darley, MBBS, Bc(Hons II) and Erika D. Lease, MD

 

6:00 PM	(441) The Accuracy of LAS in Predicting Post-Transplant Risk of ECMO Recipients J. Katsis, W. F. Parker, M. Churpek, E. Garrity. Pulmonary and Critical Care, University of Chicago, Chicago, IL
6:05 PM	(442) The Protective Effect of Prone Positioning on Human Rejected Donor Lungs during Cellular Ex Vivo Lung Perfusion H. Niikawa1, T. Okamoto1, K. S. Ayyat1, Y. Itoda1, C. F. Farver2, K. R. McCurry1. 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 2Anatomic Pathology, Cleveland Clinic, Cleveland, OH
6:10 PM	(443) Evaluation of the Effects of the Correction of Hydroelectrolytic Disorders during Prolonged Ex-Vivo Lung Perfusion J. Issard, B. Decante, J. Guihaire, D. Mitilian, D. Boulate, S. Mussot, D. Fabre, E. Fadel, O. Mercier. Thoracic and Vascular Surgery, Hopital Marie Lannelongue, Paris, France
6:15 PM	(444) Donor Lung Weight at Lung Procurement; Predictive Value for Transplant Suitability during Ex Vivo Lung Perfusion T. Okamoto, H. Niikawa, D. Wheeler, B. Soliman, K. S. Ayyat, Y. Itoda, K. R. McCurry. Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH
6:20 PM	(445) Impact of Lung Allograft Oversizing on Pleural Cavity Expansion in Transplant Recipients with Idiopathic Pulmonary Fibrosis S. H. Roberts1, S. L. Miter1, B. Shukrullah2, B. C. Keller1, M. E. Lee1, T. Yurjevic1, S. Carter1, A. Pope-Harman1, P. Lee1, B. A. Whitson1. 1The Ohio State University Wexner Medical Center, Columbus, OH, 2Minneapolis Heart Institute, Minneapolis, MN
6:25 PM	(446) Single Lung Transplant Compared with Double Lung Transplant in Older Adults with Interstitial Lung Disease L. J. Benvenuto1, M. Aversa1, L. Shah1, M. Carroll1, F. D'Ovidio2, B. P. Stanifer2, J. R. Sonett2, H. Y. Robbins1, S. Arcasoy1. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY
6:30 PM	(447) Right Single and Double Lung Transplant Outperform Left Single Lung Transplant in Chronic Obstructive Pulmonary Disease: A UNOS Analysis L. J. Benvenuto1, J. Costa2, D. Piloni2, M. Aversa1, H. Y. Robbins1, L. Shah1, B. P. Stanifer2, S. Arcasoy1, J. R. Sonett2, F. D'Ovidio2. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY
6:35 PM	(448) Initial Experience with Non-Perfused Organ Donors for Lung Transplantation Y. Watanabe1, A. Healey2, M. Scott2, S. Lavery2, K. Johnson2, C. Mills2, M. Galasso1, M. Chen1, J. Yeung1, L. Donahoe1, A. Pierre1, M. de Perrot1, K. Yasufuku1, T. K. Waddell1, S. Keshavjee1, M. Cypel1. 1Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada, 2Trillium Gift of Life Network, Toronto, ON, Canada
6:40 PM	(449) Time from Lung Transplant Donor Brain Death to Cross Clamp: An Analysis of the UNOS Registry O. K. Jawitz, V. Raman, Y. Barac, M. Mulvihill, C. Moore, A. Choi, M. Hartwig, J. Klapper. Department of Surgery, Duke University School of Medicine, Durham, NC
6:45 PM	(450) Living-Donor Lobar Lung Transplantation with Undersized Lobar Grafts Can Provide Comparable Long-Term Pulmonary Function and Exercise Capacity to Cadaveric Lung Transplantation D. Nakajima, T. F. Chen-Yoshikawa, T. Menju, T. Sato, M. Sonobe, Y. Yamada, Y. Yutaka, A. Ohsumi, M. Hamaji, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan
6:50 PM	(451) Predicted Total Lung Capacity Ratio between Donors and Recipients Does Not Predict Outcomes in Non-Volume Reduced Lung Transplantation R. Poyanmehr1, W. Sommer1, F. Ius1, J. Salman1, T. Siemeni1, M. Avsar1, C. Kühn1, M. Greer2, J. Gottlieb2, T. Welte2, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Departement of Cardiothoracic Surgery, Medizinische Hochschule Hannover, Hannover, Germany, 2Departement of Pneumology, Medizinische Hochschule Hannover, Hannover, Germany
6:55 PM	(452) Human (Mesenchymal Stem Cells) SC Loaded Single Lung Allograft A. Grant1, R. R. Gonzalez2, N. Sinha3, B. Forsberg4, A. Klima4, A. Patel5, C. Piechazeck6, R. Vianna7, M. Mirsaeidi8, M. Loebe9, A. Ghodsizad10. 1Department of Surgery, Trauma and Surgical Critical Care Grady Memorial Hospital Emory University School of Medicine, Atlanta, GA, 2Surgery, Miami Transplant Institute University of Miami, Miami, FL, 3Miami Transplant Institute, Memorial Jackson Health System, University of Miami Leonard M Miller School of Medicine, Miami, FL, 4Comprehensive Care Services, Inc., Livonia, MI, 5Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, 6Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, 7Department of Surgery, Liver, Intestinal and Multivisceral Transplant, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, 8Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Miami Leonard M Miller School of Medicine, Miami, FL, 9Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, 10Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX
Secondary Audience: ID, PATH

Chairs: Stephane Collaud, MD and Walter Klepetko, MD
 

10:30 AM	(231) 5-Year Results from the ISHLT DCD Lung Transplant Registry Confirm Excellent Recipient Survival from Donation after Circulatory Death Donors D. E. Van Raemdonck1, S. Keshavjee2, B. Levvey3, W. S. Cherikh4, G. Snell3, M. E. Erasmus5, A. Simon6, A. Glanville7, S. Clark8, F. D'Ovidio9, P. Catarino10, K. McCurry11, M. Hertz12, R. Venkateswaran13, P. Hopkins14, I. Inci15, R. Walia16, D. Kreisel17, J. Mascaro18, D. F. Dilling19, P. Camp20, D. Mason21, M. Musk22, M. Burch23, A. Fisher8, R. Yusen17, J. Stehlik24, M. Cypel2. 1University Hospitals Leuven, Leuven, Belgium, 2University of Toronto, Toronto, ON, Canada, 3Alfred Hospital, Melbourne, Australia, 4UNOS, Richmond, VA, 5University Medical Center Groningen, Groningen, Netherlands, 6Harefield Hospital, London, United Kingdom, 7St Vincent's Hospital, Sydney, Australia, 8Freeman Hospital, Newcastle upon Tyne, United Kingdom, 9Columbia University Presbyterian Hospital, New York, NY, 10Royal Papworth Hospital, Cambridge, United Kingdom, 11Cleveland Clinic, Cleveland, OH, 12University of Minnesota, Minneapolis, MN, 13Wythenshawe Hospital, Manchester, United Kingdom, 14The Prince Charles Hospital, Brisbane, Australia, 15University Hospital Zurich, Zurich, Switzerland, 16St. Joseph's Hospital & Medical Center, Phoenix, AZ, 17Washington University, St Louis, MO, 18University Hospitals Birmingham, Birmingham, United Kingdom, 19Loyola University Medical Center, Chicago, IL, 20Brigham and Womens Hospital, Boston, MA, 21Baylor University Medical Center, Dallas, TX, 22Fiona Stanley Hospital, Perth, Australia, 23Great Ormond Street for Children, London, United Kingdom, 24University of Utah, Salt Lake City, UT
10:45 AM	(232) Estimated Impact of Hepatitis C Positive Lung Donor Utilization on US Donor Lung Supply J. Mooney, N. Purington, P. Mohabir, G. Dhillon. Department of Medicine, Stanford University School of Medicine, Stanford, CA
11:00 AM	(233) Center Variability in Organ Offer Acceptance and Waitlist Mortality in Lung Transplantation A. Y. Choi1, M. S. Mulvihill2, J. Weber3, H. Lee3, M. L. Cox2, B. A. Yerokun2, M. Kuchibhatla3, J. A. Klapper2, M. G. Hartwig2. 1Duke University School of Medicine, Durham, NC, 2Department of Surgery, Duke University Medical Center, Durham, NC, 3Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC
11:15 AM	(234) Donation after Circulatory Death (DCD): A 10-Year Experience in Bilateral Lung Allograft Survival at a Single Australian Center D. R. Darley, M. Benzimra, R. Pearson, M. Malouf, A. Glanville, A. Havryk, M. Plit. Lung Transplantation, St Vincent's Hospital, Sydney, Australia
11:30 AM	(235) The Impact of the Calculated Panel Reactive Antibody Value on Wait List Outcomes for Lung Transplant Candidates M. Aversa1, L. Benvenuto1, H. Kim1, L. Shah1, H. Robbins1, B. P. Stanifer1, F. D'Ovidio1, E. Vasilescu2, J. Sonett1, S. Arcasoy1. 1Lung Transplant Program, Columbia University Medical Center, New York, NY, 2Pathology and Cell Biology, Columbia University Medical Center, New York, NY
11:45 AM	(236) Utilization of PHS Increased Risk Donors in Lung Transplant Reduces Median Waitlist Time without Reducing Survival T. Khuu1, R. Chand2, C. Lum2, A. Salimbangon3, A. Chang1, D. Ross4, A. Ardehali5, E. DePasquale1. 1Transplant Services, UCLA, Los Angeles, CA, 2Medicine, Cardiology, UCLA, Los Angeles, CA, 3Transplant Service, UCLA, Los Angeles, CA, 4Medicine, Pulmonology, UCLA, Los Angeles, CA, 5Surgery, UCLA, Los Angeles, CA
12:00 PM	(237) Donor-Recipient Size Matching via Chest X-ray Measurements and Primary Graft Dysfunction Risk in Lung Transplantation D. Li, J. Weinkauf, D. Lien, A. Kapasi, A. Hirji, K. Halloran. Department of Medicine, University of Alberta, Edmonton, AB, Canada

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: ID

Session Summary: Patients with end stage heart and lung disease outnumber the annual thoracic transplants. Maximizing donor utilization is a key factor to addressing this imbalance, but donor management varies greatly across regions leading to significant heterogeneity in donor utilization. This symposium will describe proven and developing strategies for donor management to increase organ utilization as well as identify future directions and opportunities for improvement.

Chairs: Aleem Siddique, MBBS and Sakhee Kotecha, MBBS (Hons)
 

2:00 PM	Yin and Yang? Goal Directed Thoracic Organ Optimization Does Not Compromise Abdominal Organs Arne Neyrinck, MD, PhD, University Hospitals Leuven, Leuven, Belgium
2:15 PM	Practical Steps to Optimize the Heart and Lungs: The UK Experience Rajamiyer Venkateswaran, FRCS, Wythenshawe Hospital, Manchester, UK
2:30 PM	Carpe Diem - On the Cusp of an Explosion? Research in Donor Management George B. Mallory, Jr., MD, Texas Children’s Hospital, Houston, TX, USA
2:45 PM	Impact of Using Infection Risk Donors Including NAT +HCV Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada
3:00 PM	Making the Most in DCD Lung Transplant Dirk Van Raemdonck, MD, PhD, University Hospitals, Leuven, Belgium
3:15 PM	Use of Older Donors for Lung Transplantation: How Old is Too Old? Jonathan Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA
3:30 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX
Secondary Audience: NHSAH, PHARM

Chairs: Robert D. Levy, MD, FRCPC and Jonathan P. Singer, MD, MS
 

4:15 PM	(273) ISHLT Consensus on Standardization of Bronchoalveolar Lavage in Lung Transplantation T. Martinu1, A. Koutsokera2, C. Benden2, E. Cantu3, D. Chambers4, M. Cypel1, J. Edelman5, A. Emtiazjoo6, A. J. Fisher7, J. R. Greenland8, D. Hayes9, D. M. Hwang10, B. C. Keller11, E. D. Lease12, M. Perch13, M. Sato14, J. L. Todd15, S. Verleden16, J. von der Thüsen17, S. S. Weigt18, S. Keshavjee1, *. On Behalf of ISHLT BAL Stansdardization Workgroup1. 1Toronto Lung Transplant Program, Toronto, ON, Canada, 2University Hospital Zurich, Zurich, Switzerland, 3University Hospital of Pennsylvania, Philadelphia, PA, 4The Prince Charles Hospital, Brisbane, Australia, 5Puget Sound VAMC, Seattle, WA, 6University of Florida, Gainesville, FL, 7Freeman Hospital, Newcastle, United Kingdom, 8University of California San Francisco, San Francisco, CA, 9Nationwide Children’s Hospital, Columbus, OH, 10Toronto General Hospital Research Institute, Toronto, ON, Canada, 11The Ohio State University, Columbus, OH, 12University of Washington, Seattle, WA, 13Rigshospitalet, Copenhagen, Denmark, 14University of Tokyo, Tokyo, Japan, 15Duke University Medical Canter, Durham, NC, 16Katholieke Universiteit Leuven, Leuven, Belgium, 17Erasmus Medical Center, Rotterdam, Netherlands, 18University of California Los Angeles, Los Angeles, CA
4:30 PM	(274) Reduced Frailty after Lung Transplant is Associated with Survival A. Venado1, C. Huang2, D. V. Glidden2, A. Soong1, Y. Gao1, S. Hays1, J. Golden1, J. Kukreja3, L. E. Leard1, R. Shah1, M. Kleinhenz1, J. Greenland1, J. P. Singer1. 1Pulmonary & Critical Care, University of California, San Francisco, San Francisco, CA, 2Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, 3Cardiothoracic Surgery, University of California, San Francisco, San Francisco, CA
4:45 PM	(275) A Combination of Delayed Gastric Emptying and Gastroesophageal Reflux Disease is Associated with Worse Outcomes in Lung Transplantation J. Fernandez-Castillo, E. Huszti, K. C. Zhang, R. Ghany, L. Levy, D. R. Darley, C. Chaparro, J. Tikkanen, S. Keshavjee, L. Singer, J. C. Yeung, T. Martinu. University of Toronto/UHN, Toronto, ON, Canada
5:00 PM	(276) Ten-Year-Experience with Alemtuzumab as Induction Therapy: A Single-Center Analysis of More Than 500 Patients A. Benazzo1, S. Schwarz1, D. Weber2, G. Murakozy1, C. Lambers2, B. Moser1, J. Matilla1, G. Lang2, S. Taghavi1, W. Klepetko1, K. Hoetzenecker1, P. Jaksch1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
5:15 PM	(277) Extracorporeal Photopheresis Improves Survival Probability and Lowers Hospital-Related Expenses In Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome C. Joukhadar1, R. Knobler2, A. Cho2, U. Just2, G. Muraközy3, P. Jaksch3. 1J&P Medical Research Ltd, Vienna, Austria, 2Department of Dermatology, Medical University of Vienna, Vienna, Austria, 3Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
5:30 PM	(278) Sirolimus + Tacrolimus Maintenance with No Induction Therapy May Maximize Survival in Lung Transplant Recipients M. Wijesinha, J. Hirshon, M. Terrin, L. Magder, C. Brown, K. Stafford, A. Iacono. University of Maryland School of Medicine, Baltimore, MD
5:45 PM	(279) End Stage Renal Disease after Lung Transplantation: An 11-Year National Cohort Study M. Kosztowski, X. Luo, J. Garonzik-Wang, R. Higgins, D. L. Segev, E. Bush. Department of Surgery, Johns Hopkins, Baltimore, MD

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Lung Failure/Transplantation (Adult) (Banda Sea 1)
(LF/LTX)   Poster Numbers: 1014-1063

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: ID, NHSAH, PEDS

Session Summary: Guidelines for lung transplant candidacy were last updated in 2014 and include significant numbers of absolute and strong relative contraindications. In the last 5 years there has been a dramatic increase in the willingness of transplant programs to push the boundaries of transplant candidacy and a concomitant increase in the published literature regarding extended criteria recipients. This symposium focuses on several potential avenues for increased lung transplant candidate access.

Chairs: Edward Cantu, III, MD and Mark Benzimra, MD
 

7:00 AM	Is HIV a Contra-Indication for Lung Transplant? Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy
7:15 AM	Scleroderma: The Ability to Swallow is Optional Maria M. Crespo, MD, University of Pennsylvania, Philadelphia, PA, USA
7:30 AM	So Many Antibodies... Adriana Zeevi, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
7:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: PH

Session Summary: Lung allocation in the United States recently moved to broader geographic sharing. This symposium will review lung allocation throughout the world as it relates to this concept. Topics will include an overview of international lung allocation, the US lung allocation system, review of modeled data on this principle, updated US data available since policy implementation, and a review of this concept as it affects allocation over greater distances in Canada and Australia.

Chairs: Duane M. Davis, MD and James L. Lordan, MB, FRCP
 

10:15 AM	Lung Allocation Systems: Similarities and Differences Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
10:30 AM	Q&A
10:35 AM	Changes in US Lung Allocation: Support for Broader Sharing Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH, USA
10:50 AM	Q&A
10:55 AM	Implementation of 250 Nautical Miles as the First Region of Lung Allocation in the US: Early Results Kevin Chan, MD, University of Michigan, Ann Arbor, MI, USA
11:10 AM	Q&A
11:15 AM	Effects of Distance on Lung Allocation in Australia/New Zealand Dan Chambers, MBBS, FRACP, The Prince Charles Hospital, Brisbane, Australia
11:35 AM	Q&A
11:35 AM	Effects of Distance on Lung Allocation in Canada Alim Hirji, MD, University of Alberta, Edmonton, AB, Canada
11:50 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PATH

Chairs: Alejandro M. F. Bertolotti, Sr., MD and Clemens Aigner, MD
 

12:15 PM	(336) The New View of Pre-Lung Transplant Determinants for Predicting De Novo Donor Specific Antibody and Transplant Rejection A. Zhang1, D. Thomas1, J. Allen1, K. McCurry2, M. Budev2. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH
12:30 PM	(337) Inflammatory Events Precede Development of De Novo DSA after Lung Transplantation I. L. Ponor1, A. Jackson2, A. Cochrane3, I. Tunc4, M. Jang4, J. Mathew5, N. D’Emilio6, H. I. Luikart6, I. Timofte7, A. Brown8, P. Shah9, S. Nathan8, A. Iacono7, J. B. Orens9, C. Marboe10, G. J. Berry11, K. Khush12, H. Valantine13, S. Agbor-Enoh14. 1Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, 2Medicine-Immunogenetics and Transplantation Immunology, The Johns Hopkins University, Baltimore, MD, 3Medicine, Inova Fairfax Hospital, Fairfax, VA, 4Division of Intramural Research, National Heart, Lung, and Blood Institute -NIH, Bethesda, MD, 5Pulmonary and Critical Care, The Johns Hopkins School of Medicine, Baltimore, MD, 6Division of Cardiology, Stanford University School of Medicine, Stanford, CA, 7Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, 8Inova Heart and Vascular Institute, Inova Fairfax Hospital, Fairfax, VA, 9Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, 10Pathology, New York Presbyterian University Hospital of Cornell and Columbia, New York, NY, 11Pathology, Stanford University School of Medicine, Palo Alto, CA, 12Cardiology, Stanford University School of Medicine, Palo Alto, CA, 13Division of Intramural Research, National Heart, Lung, and Blood Institute- NIH, Bethesda, MD, 14Division of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD
12:45 PM	(338) Transcriptome Profiles of the Circulating Extracellular Vesicles in Acute Lung Allograft Rejection S. Joo1, M. Puhka2, R. Krebs1, P. Mattila3, M. Kankainen3, K. Dhaygude1, E. Rouvinen1, K. Lemström1. 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland, 2EV core, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 3Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
1:00 PM	(339) Profiling Pre-Existing Autoantibodies for Prediction of Primary Graft Dysfunction V. Kaza1, C. Zhu1, L. Feng1, A. Reddy2, L. Terada1, M. Mohanka1, C. Lacelle3, S. Bollineni1, A. Banga1, J. Mullins1, F. Torres1, Q. Li1. 1Internal Medicine, UT Southwestern Medical Center, Dallas, TX, 2Internal Medicine, Southwest Pulmonary Associates, Dallas, TX, 3UT Southwestern Medical Center, Dallas, TX
1:15 PM	(340) Correlation between Early B and NK Cell Frequencies and in Relation to CLAD Development and PGD 24h after Lung Transplantation A. Knoefel1, F. Ius1, T. Nakagiri1, J. Salman1, T. Siemeni1, W. Sommer1, C. Kuehn1, M. Avsar1, T. Welte2, I. Tudorache1, C. S. Falk3, A. Haverich1, G. Warnecke1. 1HTTG, MHH, Hannover, Germany, 2Pneumology, MHH, Hannover, Germany, 3Transplant Immunology, MHH, Hannover, Germany
1:30 PM	(341) miRNAs in Lung Transplantation: Small Things That Make Big Differences V. Vaira1, V. S. Musso2, A. Terrasi1, G. Gaudioso3, S. Ferreo3, V. Rossetti3, L. C. Morlacchi3, D. Tosi2, A. Palleschi2. 1Università degli Studi of Milan, Milan, Italy, 2Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, 3Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
1:45 PM	(342) Risk Factors for Primary Graft Dysfunction in Patients with Cystic Fibrosis Receiving Lung Transplants J. A. Martin1, M. K. Porteous1, E. Cantu2, D. J. Lederer3, L. Snyder4, A. Weinacker5, J. B. Orens6, P. D. Shah6, V. N. Lama7, J. McDyer8, K. M. Wille9, C. A. Hage10, J. Singer11, L. B. Ware12, M. Oyster1, M. Brown1, J. D. Christie1, J. M. Diamond1. 1Medicine, University of Pennsylvania, Philadelphia, PA, 2Surgery, University of Pennsylvania, Philadelphia, PA, 3Medicine, Columbia University, New York, NY, 4Medicine, Duke University, Durham, NC, 5Medicine, Stanford University, Palo Alto, CA, 6Medicine, Johns Hopkins University, Baltimore, MD, 7Medicine, University of Michigan, Ann Arbor, MI, 8Medicine, University of Pittsburgh, Pittsburgh, PA, 9Medicine, University of Alabama at Birmingham, Birmingham, AL, 10Medicine, Indiana University, Indianapolis, IN, 11Medicine, University of California San Francisco, San Francisco, CA, 12Medicine, Vanderbilt University, Nashville, TN